Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for H... (itis dyspnea pulmonary infiltrates pneum...)

HOME >> MEDICINE >> TECHNOLOGY

Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C

Date:11/2/2009

itis, dyspnea, pulmonary infiltrates, pneumonia, interstitial pneumonitis, pulmonary hypertension, hepatic failure, increases in serum creatinine in patients with renal insufficiency, acute hypersensitivity (angioedema, bronchoconstriction, anaphylaxis and cutaneous eruptions), hypertriglyceridemia, and peripheral neuropathy.

During the course of therapy lasting up to 48 weeks in patients ages 3 through 17 years receiving PEGINTRON/REBETOL combination therapy, weight loss and growth inhibition were common.

Please see full prescribing information at http://www.spfiles.com/pipeg-intron.pdf.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential market for narlaprevir, PEGINTRON and REBETOL. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, includin
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment

Post Your Comments:

(Date:12/15/2009)... -- Medical researchers with EDP Biotech Corporation (EDP) ... technology for a simple blood test to detect ... success of its pre-clinical trials for the ColoMarker(TM) ... biomarker, CA11-19, and all aspects of its use. ... detect colon cancer in its earliest, most curable ...

(Date:12/15/2009)... Dec. 15 Certified healthcare providers who ... complications from the H1N1 flu virus may now ... the Department of Health announced today. ,, ... everyone because approximately 3.2 million doses of vaccine ... it to individuals in the priority groups. ,, ...

(Date:12/15/2009)... Dec. 15 ,, Reportlinker.com announces ... available in its catalogue: ,, Hepatitis ... Forecasts to 2015 ,, http://www.reportlinker.com/p0167309/Hepatitis-B-Vaccines---Pipeline-Analysis-and-Market-Forecasts-to-2015.html ... Analysis and Market Forecasts to 2015 ,, ... analysis specialist,s new report, "Hepatitis B Vaccines ...

Breaking Medicine Technology:Researchers Announce Medical Breakthrough with Simple, Inexpensive Blood Test for Colon Cancer 2 Department of Health Urges Expanded H1N1 Vaccination Efforts to Include All Patients 2 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 2 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 3 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 4 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 5 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 6 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 7 Are the monoamines involved in shaping conduct disorders 3F 9898 1 Are the monoamines involved in shaping conduct disorders 3F 9898 2 Are the monoamines involved in shaping conduct disorders 3F 9898 3 Are the monoamines involved in shaping conduct disorders 3F 9898 4 Are the monoamines involved in shaping conduct disorders 3F 9898 5 Are the monoamines involved in shaping conduct disorders 3F 9898 6 Hormone promises to keep joint injuries from causing long term osteoarthritis 56985 1 Hormone promises to keep joint injuries from causing long term osteoarthritis 56985 2 Hormone promises to keep joint injuries from causing long term osteoarthritis 56985 3 Hormone promises to keep joint injuries from causing long term osteoarthritis 56985 4 For Organ Donation Intent and Reality Dont Align 56981 1 For Organ Donation Intent and Reality Dont Align 56981 2 For Organ Donation Intent and Reality Dont Align 56981 3

[0] Researchers Announce Medical Breakthrough with Simple, Inexpensive Blood Test for Colon Cancer [0] Department of Health Urges Expanded H1N1 Vaccination Efforts to Include All Patients [0] Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015

... Menopause Society 19th Annual ... Meeting, ... present an abstract in a presentation on their new drug,candidate, VG101, for ... American Menopause Society in Orlando, Florida on,September 26, 2008. Dr. Mary Tagliaferri, ...

... LAUSANNE, Switzerland, September 25 Debiopharm Group,(Debiopharm), ... serious medical conditions and particularly oncology, announces,the ... Agencies for the approval of,its new 6-month ... luteinizing hormone releasing hormone (LHRH) agonist for ...

Other Medicine Technology:Bionovo's VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness 2 Bionovo's VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness 3 Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients 2

Bionovo's VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients

(Date:12/15/2009)... Authority, Ban on Annual Benefit Limits, & Effective ... -- Consumer Watchdog condemned the removal of the ... the public option from the U.S. Senate health ... Senate must still make three essential fixes to ... entire health care system to the insurance industry. ...

(Date:12/15/2009)... Palo Alto Networks(TM), the network security company, today ... Series next-generation firewalls for accurate threat prevention on ... control over applications such as peer-to-peer file sharing. ... with eight facilities on five campuses. The university ... of academic schools and institutions throughout Japan. It ...

(Date:12/15/2009)... Dec. 15 Our Lady of Lourdes Health ... Jersey hospitals, has agreed to pay the United States ... Medicare, the Justice Department announced today. The two hospitals ... Camden, N.J., and Lourdes Medical Center of Burlington County ... defendant in a suit brought by a whistleblower, Tony ...

(Date:12/15/2009)... risk, research finds , , TUESDAY, Dec. 15 (HealthDay News) ... regulates appetite, may guard against Alzheimer,s disease, new research ... may be one of many agents that we use ... study author Dr. Sudha Seshadri, an associate professor of ... may be one of many markers that we measure ...

(Date:12/15/2009)... CDC have released some sobering statistics concerning the parallel rise in ... employers an effective means of combating this trend afflicting their workforce. ... ... Rates of diabetes are climbing across America due in large part ... the American Diabetes Association has stated that the rate of diabetes ...

Breaking Medicine News(10 mins):Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 2 Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 3 Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 4 Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 5 Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2 Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3 Health News:Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations 2 Health News:Fat Hormone May Protect Against Alzheimer's 2 Health News:Fat Hormone May Protect Against Alzheimer's 3 Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 2 Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 3

[0] The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System [0] Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University [0] Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations [0] Fat Hormone May Protect Against Alzheimer's [2] TrekDesk: A Potentially Positive Impact on Diabetes & Obesity

... Pharmaceutical product teams,have the power to make ... The problem is,launch teams often lack the right ... only produce a sub-optimal launch. In fact, ... and cross-functional team work are key ingredients,during product ...

... Advancement of Novel Technology and ... Product Portfolio, ... therapeutic antibody product company, today announced that,it has raised $33.9 million ... participating significantly in the round were Frazier,Healthcare Ventures and Alloy Ventures, ...

... CHICO, Calif., Nov. 8 State,Compensation Insurance Fund ... part of State Fund,s Employer Education Series, featuring ... Back,Connection(TM). The three-hour seminar entitled "Watch Your Back",introduces ... how they,can involve the very people they are ...

... InteKrin Therapeutics, Inc.,a privately-held clinical stage biopharmaceutical ... drugs for the treatment of,diabetes and cardio-metabolic diseases, ... the company as Chief Medical Officer. Dr. DePaoli,will ... and will be,responsible for the clinical development of ...

... $7.5 Million in 2008, OTTAWA, Canada, ... Natural Nutrition press release is, http://www.naturalnutritioninc.com . ... (OTC Bulletin Board: NNTN), http://www.naturalnutritioninc.com has ... adding state-of-the-art equipment to produce,sheeted protein and ...

... On November 9, the,Department of Veterans Affairs ... award one contract to conduct two important technical ... the updating of our military,disability system. The studies ... on Care for America,s Returning Wounded Warriors,co-chaired by ...

Other Medicine News:Health News:Pharmaceutical Product Commercialization: Enabling Teams to Excel 2 Health News:Pharmaceutical Product Commercialization: Enabling Teams to Excel 3 Health News:Anaptys Biosciences Raises Over $33 Million in Series B Financing 2 Health News:Anaptys Biosciences Raises Over $33 Million in Series B Financing 3 Health News:Free Seminar Features State Fund's Back Connection(TM), November 14, in Chico 2 Health News:Free Seminar Features State Fund's Back Connection(TM), November 14, in Chico 3 Health News:InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer 2 Health News:InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer 3 Health News:Corrected & Replaced - Natural Nutrition Expands Revenue Capabilities with Newly Installed State of the Art Nutrition Bar Line 2 Health News:Modernizing and Improving the Disability and Compensation Systems 2 Health News:Modernizing and Improving the Disability and Compensation Systems 3

Pharmaceutical Product Commercialization: Enabling Teams to Excel Anaptys Biosciences Raises Over $33 Million in Series B Financing Free Seminar Features State Fund's Back Connection(TM), November 14, in Chico InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer Corrected & Replaced - Natural Nutrition Expands Revenue Capabilities with Newly Installed State of the Art Nutrition Bar Line Modernizing and Improving the Disability and Compensation Systems

McIntyre-Binkhorst, length 18 mm....

Wilbrandt-Binkhorst Cannula have a smooth blunt tip end opening....

Wire lid retractor may be clamped to surgical drape with suture or elastic band. Large pair....

Rigid neck rake retractor, 3 sharp prong....

Medicine Products:

McIntyre-Binkhorst Wilbrandt-Binkhorst Cannula Jaffe Speculums Rigid Neck Rake Retractor

Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for H...(itis dyspnea pulmonary infiltrates pneum...),Health